Brooks O'Neil
Stock Analyst at Lake Street
(1.75)
# 3,326
Out of 5,008 analysts
36
Total ratings
36.36%
Success rate
-9.54%
Average return
Main Sectors:
Stocks Rated by Brooks O'Neil
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNDM Tandem Diabetes Care | Downgrades: Hold | $75 → $12 | $15.01 | -20.05% | 2 | Aug 11, 2025 | |
| RCEL AVITA Medical | Maintains: Buy | $14 → $8 | $5.52 | +44.93% | 7 | Aug 11, 2025 | |
| LFMD LifeMD | Maintains: Buy | $18 → $14 | $6.94 | +101.73% | 3 | Aug 6, 2025 | |
| PIII P3 Health Partners | Maintains: Buy | $50 → $20 | $8.91 | +124.47% | 2 | Apr 21, 2025 | |
| SRDX Surmodics | Upgrades: Buy | $43 | $28.70 | +49.83% | 4 | Mar 7, 2025 | |
| LMAT LeMaitre Vascular | Maintains: Buy | $105 → $110 | $87.49 | +25.73% | 2 | Feb 28, 2025 | |
| BBNX Beta Bionics | Initiates: Buy | $30 | $21.95 | +36.67% | 1 | Feb 24, 2025 | |
| SMLR Semler Scientific | Maintains: Buy | $40 → $71 | $30.75 | +130.89% | 1 | Jan 24, 2025 | |
| LFVN LifeVantage | Initiates: Buy | $26 | $9.51 | +173.40% | 1 | Dec 19, 2024 | |
| HROW Harrow | Maintains: Buy | $45 → $55 | $42.16 | +30.46% | 3 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $18 | $13.60 | +32.35% | 4 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $4.20 | +19.05% | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $7.31 | +64.16% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $26 | $24.77 | +4.97% | 2 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $0.68 | +1,514.56% | 1 | Apr 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $128 | $40.82 | +212.35% | 1 | Sep 15, 2020 |
Tandem Diabetes Care
Aug 11, 2025
Downgrades: Hold
Price Target: $75 → $12
Current: $15.01
Upside: -20.05%
AVITA Medical
Aug 11, 2025
Maintains: Buy
Price Target: $14 → $8
Current: $5.52
Upside: +44.93%
LifeMD
Aug 6, 2025
Maintains: Buy
Price Target: $18 → $14
Current: $6.94
Upside: +101.73%
P3 Health Partners
Apr 21, 2025
Maintains: Buy
Price Target: $50 → $20
Current: $8.91
Upside: +124.47%
Surmodics
Mar 7, 2025
Upgrades: Buy
Price Target: $43
Current: $28.70
Upside: +49.83%
LeMaitre Vascular
Feb 28, 2025
Maintains: Buy
Price Target: $105 → $110
Current: $87.49
Upside: +25.73%
Beta Bionics
Feb 24, 2025
Initiates: Buy
Price Target: $30
Current: $21.95
Upside: +36.67%
Semler Scientific
Jan 24, 2025
Maintains: Buy
Price Target: $40 → $71
Current: $30.75
Upside: +130.89%
LifeVantage
Dec 19, 2024
Initiates: Buy
Price Target: $26
Current: $9.51
Upside: +173.40%
Harrow
Oct 4, 2024
Maintains: Buy
Price Target: $45 → $55
Current: $42.16
Upside: +30.46%
Sep 3, 2024
Maintains: Buy
Price Target: $32 → $18
Current: $13.60
Upside: +32.35%
Jun 28, 2024
Initiates: Buy
Price Target: $5
Current: $4.20
Upside: +19.05%
Mar 7, 2024
Initiates: Buy
Price Target: $12
Current: $7.31
Upside: +64.16%
Feb 15, 2023
Maintains: Buy
Price Target: $20 → $26
Current: $24.77
Upside: +4.97%
Apr 8, 2022
Initiates: Buy
Price Target: $11
Current: $0.68
Upside: +1,514.56%
Sep 15, 2020
Initiates: Buy
Price Target: $128
Current: $40.82
Upside: +212.35%